Cytokine & Growth Factor Reviews ( IF 9.3 ) Pub Date : 2019-10-22 , DOI: 10.1016/j.cytogfr.2019.10.005 Lehe Yang 1 , Shichong Lin 2 , Lingyuan Xu 2 , Jiayuh Lin 3 , Chengguang Zhao 4 , Xiaoying Huang 5
|
Excessive activation of signal transducer and activator of transcription 3 (STAT3) signaling is observed in a subset of many cancers, making activated STAT3 a highly promising potential therapeutic target supported by multiple preclinical and clinical studies. However, early-phase clinical trials have produced mixed results with STAT3-targeted cancer therapies, revealing substantial complexity to targeting aberrant STAT3 signaling. This review discusses the diverse mechanisms of oncogenic activation of STAT3, and the small molecule inhibitors of STAT3 in cancer treatment.
中文翻译：
STAT3的新型激活剂和小分子抑制剂。
在许多癌症的子集中观察到信号转导子和转录激活因子3（STAT3）的过度激活，使激活的STAT3成为由多种临床前和临床研究支持的极有希望的潜在治疗靶标。但是，早期临床试验已将针对STAT3的癌症疗法的结果混合在一起，揭示了靶向STAT3异常信号转导的实质性复杂性。这篇综述讨论了STAT3致癌激活的各种机制，以及STAT3的小分子抑制剂在癌症治疗中的作用。
京公网安备 11010802027423号